Iovance

$18.50 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Iovance

Iovance Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cell therapies as novel cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company has developed a shorter manufacturing process for Tumor infiltrating lymphocyte (TIL) therapy known as Generation 2 (Gen 2), which yields a cryopreserved TIL product. Its lead product candidates include lifileucel for metastatic melanoma and LN-145 for metastatic cervical cancer. In addition to metastatic melanoma and metastatic cervical cancer, it is investigating TIL therapy and peripheral blood lymphocyte therapy for the treatment of squamous cell carcinoma of the head and neck, non-small cell lung cancer and chronic lymphocytic leukemia.

Stock Analysis

last close $18.5
1-mo return -29.4%
3-mo return -19.8%
avg daily vol. 2.23M
52-week high 54.21
52-week low 15.88
market cap. $2.9B
forward pe -
annual div. -
roe -44.2%
ltg forecast -
dividend yield -
annual rev. $--
inst own. -
baraka

Subscribe now for daily local and international financial news

Subscribe